U.S. Markets open in 8 hrs 39 mins

Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study

·1 min read
  • Merck & Co Inc (NYSE: MRKwill stop for futility the Phase 3 LYNK-003 trial of Lynparza with or without bevacizumab for unresectable or metastatic colorectal cancer who have not progressed following first-line induction.

  • The action follows the recommendation of an independent Data Monitoring Committee (DMC) after the DMC reviewed the data from a planned interim analysis.

  • Related: Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients.

  • Lynparza is a PARP inhibitor co-developed and co-commercialized with AstraZeneca Plc (NASDAQ: AZN).

  • At the pre-specified interim analysis for progression-free survival, the efficacy of Lynparza as a monotherapy and in combination with bevacizumab relative to control met the criteria for futility. Both experimental arms will be discontinued.

  • No new safety signals were observed with Lynparza in the 309-subject trial.

  • Price Action: MRK shares are up 0.06% at $92.40, and AZN shares are up 2.55% at $68.06 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.